For some medicines, the challenge is not just whether they can combat disease but also if they can survive the journey, reach the correct site, and respond at the right moment. This patent applies that challenge to rheumatoid arthritis by creating a nanocarrier that locates inflamed joints before reacting to the disease environment. It uses celastrol, a natural anti-inflammatory compound limited by poor solubility and toxicity. The researchers loaded celastrol into porous silica nanoparticles with a lipid layer that acts as a gate, slowing drug release normally. In inflamed tissue, high reactive oxygen species (ROS) break the gate, speeding release. They further enhanced navigation by coating particles with M2 macrophage membranes, which can interact with inflammatory signals. In arthritic rats, these membrane-coated particles accumulated more in inflamed joints, about 2.5 times more fluorescence at six hours compared to uncoated ones. The treatment achieved the lowest arthritis scores among tested formulations, 2.7 versus 12.1 in untreated rats, and reduced bone erosion and inflammatory markers. These are preclinical results, not proven in humans. This invention marks a shift: the carrier is designed not just to deliver medicine but to recognize inflammation and release its cargo based on the diseased environment.
A medicine that waits for the inflammation before releasing its payload
Patent number: CN 119112839 A
Inventor(s): X. Wang, Y. Xiao, and X. Zhang
Citation: X. Wang, Y. Xiao, and X. Zhang, “巨噬细胞膜包被ROS响应性仿生纳米递药系统、制备及应用 [Macrophage-membrane-coated ROS-responsive biomimetic nanodrug delivery system, preparation and application],” China Patent CN 119112839 A, Dec. 13, 2024.
